Drug profile · INN
telavancin
VIBATIV
telavancin (VIBATIV) is an FDA-listed pharmaceutical active ingredient. Associated with Theravance Biopharma Ireland Umited. Route of administration: injection. Current US regulatory status: approved.
Drug details — telavancin
- US status
- approved
- Class
- Antiinfectives for systemic use (J01)
- Route
- INJECTION
- Patents
- 20
- Programs
- 11
- Data quality
- 0.89
Quick answer
telavancin (VIBATIV) is an FDA-listed pharmaceutical active ingredient. Associated with Theravance Biopharma Ireland Umited. Route of administration: injection. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 11780852
Methods for treating Crohn's disease using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile
granted -
US 11723900
4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
granted -
US 11673879
Substituted pyrimidines and methods of use
granted -
US 11642332
(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
granted -
US 11590116
Substituted pyridines and methods of use
granted -
US 11254655
Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists
granted -
US 11033533
(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
granted -
US 10946007
4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
granted -
US 10947254
Methods for treating ulcerative colitis using 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile
granted -
US 10751383
Doses and methods for administering telavancin
granted -
US 10722504
4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
granted -
US 10696656
Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists
granted -
US 10548879
(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
granted -
US 10441579
4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
granted -
US 10233172
Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists
granted -
US 10206913
4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
granted -
US 10172834
(2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
granted -
US 10138220
Diamide compounds having muscarinic receptor antagonis and beta2 adrenergic receptor agonist activity
granted -
US 10034870
4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
granted -
US 9975877
Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists
granted
Frequently asked questions
What is telavancin?
telavancin (VIBATIV) is an FDA-listed pharmaceutical active ingredient. Associated with Theravance Biopharma Ireland Umited. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for telavancin?
VIBATIV is a marketed brand name for telavancin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of telavancin?
telavancin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.